{
  "name" : "moscow.sci-hub.se_4491_9934e528c022709ebee1f70d566891e6_satalkar2015.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?",
    "authors" : [ "Priya Satalkar", "Bernice Simone Elger", "David M. Shaw" ],
    "emails" : [ "priya.satalkar@unibas.ch" ],
    "sections" : [ {
      "heading" : null,
      "text" : "nanotechnology (commonly known as nanomedicine) are expected to significantly improve disease diagnostic and therapeutic modalities and subsequently reduce health care costs. However, there is no consensus on the definition of nanotechnology or nanomedicine, and this stems from the underlying debate on defining ‘nano’. This paper aims to present the diversity in the definition of nanomedicine and its impact on the translation of basic science research in nanotechnology into clinical applications. We present the insights obtained from exploratory qualitative interviews with 46 stakeholders involved in translational nanomedicine from Europe and North America. The definition of nanomedicine has implications for many aspects of translational research including: fund allocation, patents, drug regulatory review processes and approvals, ethical review processes, clinical trials and public acceptance. Given the interdisciplinary nature of the field and common interest in developing effective clinical applications, it is important to have honest and transparent communication about nanomedicine, its benefits and potential harm. A clear and consistent definition of nanomedicine would significantly facilitate trust among various stakeholders including the general public while minimizing the risk of miscommunication and undue fear of nanotechnology and nanomedicine.\nKeywords Nanotechnology Nanomedicine Definition Ethics Qualitative research Stakeholders\n& Priya Satalkar priya.satalkar@unibas.ch\n1 Institute for Biomedical Ethics (IBMB), University of Basel, Bernoullistrasse 28, 4056 Basel,\nSwitzerland"
    }, {
      "heading" : "Introduction",
      "text" : "The use of nanotechnology in medicine has the potential to significantly improve human health and wellbeing due to highly accurate and sensitive diagnostic tests (Ferrari et al. 2009), targeted therapeutic interventions (Duncan and Gaspar 2011)and theranostic applications that have a combined approach to diagnose and treat a disease using the same intervention (Lammers et al. 2011). Nanotechnology contributes to early disease detection, better treatment outcomes, and reduced health care expenditures. The interdisciplinary field of nanotechnology and nanomedicine has gained considerable attention from academia, the pharmaceutical industry, various national and international funding and regulatory agencies and the general public (Kostarelos 2006; Wagner et al. 2006; Bawa et al. 2005; Pidgeon and RogersHayden 2007; Scheufele et al. 2009), and has made significant progress along the translational pathway in the last 15 years (Etheridge et al. 2013).\nNanotechnology has also raised a number of questions related to risk assessment, risk minimization (Hogle 2012), human and environmental toxicity (Ramachandran et al. 2012), and cost and fair access to the improved interventions across societies (Allhoff 2009). There has also been tremendous pressure to accelerate the translation of basic nano-technological research into bedside clinical applications in medicine (Kola and Landis 2004). However, a high level of uncertainty about potential risks and benefits of nanoparticles and nanomedicines creates significant hurdles along this translational pathway (Lenk and Biller-Andorno 2007; Resnik and Tinkle 2007). Particularly interesting in this regard are ‘first in human’ (FIH) trials of medical applications of nanotechnology, as they pose the highest level of uncertainty in all clinical research (Kimmelman and London 2011).\nThe goal of our research project was to document the various challenges and ethical hurdles faced by stakeholders involved in the process of planning, reviewing and conducting FIH trials in nanomedicine. In this paper, we discuss diversity in the definition of nanomedicine. We begin with the definitions of nanotechnology and nanomedicine proposed by international scientific bodies and key drug regulatory authorities. Next, we describe and discuss definitions provided by stakeholders who were interviewed in our study as compared to official definitions. Finally, we highlight concerns that arise due to the various definitions used by the stakeholders on the ethical and regulatory review process of FIH trials in nanomedicine."
    }, {
      "heading" : "Methodology",
      "text" : "We used exploratory qualitative research methods to gather insights from various stakeholders involved in translational nanomedicine. In-depth interviews were considered valuable and appropriate for this exploratory research since there are only a handful of empirical studies that investigated issues in translational research in nanomedicine.\nP. Satalkar et al."
    }, {
      "heading" : "Study Population",
      "text" : "Stakeholders in translational nanomedicine for the purpose of this study are scientists affiliated with universities, small and medium size enterprises (SMEs) and large pharmaceutical industry, members of national ethics advisory committees and institutional ethics committees (EC), physicians, representatives of the drug regulatory authorities, patient advocacy group, clinical research organizations and venture capital groups based in Europe and North America.\nStudy Instrument\nBased on available literature on this topic, we developed a list of open-ended interview questions to guide and facilitate interviews with the aforementioned stakeholders. The interview guide was pilot tested with fellow colleagues (a doctoral and a post-doctoral researcher with experience in qualitative research at the institute) and an expert in biotechnology ethics from the US to assess the clarity and validity of the questions. These pilot interviews were excluded from the final data set of 46 interviews. The interview guide allowed for a structured enquiry, but also provided interviewees with the necessary opportunity to elaborate on issues that they deemed critical. The interview guide was approved by the ethics commission of Basel Stadt and Basel Land (Ethikkommission Beider Basel EKBB) in January 2013. This commission is now called the ethics commission of North-west and Central Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ)."
    }, {
      "heading" : "Sample",
      "text" : "The interviewed experts and the stakeholders were identified through publications, university affiliations, contacts made at key scientific conferences on nanomedicine and personal and professional networks. Drug development is regulated by national(US FDA) or regional (European Medicines Agency) drug regulatory authorities, so we expected researchers planning or conducting FIH trials in nanomedicine to face distinct challenges depending on the regulatory environment in their country or the country where they planned to conduct a trial. We used a purposive sampling technique to include maximum variation in terms of the respondents’ experiences, professional backgrounds and affiliations, and geographic location. We included stakeholders with views in line with the dominant discourse and those who challenge the dominant views (Devers and Frenkel 2000; Kenen et al. 2004). This approach allowed us to explore challenges in planning, conducting and reviewing FIH trials in nanomedicine from the perspectives of various stakeholders working in multiple countries. It also facilitated a reflection on the interdisciplinary nature of nanomedicine since respondents had varied professional backgrounds, roles and responsibilities that could be explored in depth. Recruitment was further facilitated by the use of a snowball sampling technique until we reached theoretical saturation, the moment during data collection when researchers realize that no new themes are emerging (Bowen 2008). For example, in our investigation of the definition of nanomedicine as described by the stakeholders, we continued to\nDefining Nano, Nanotechnology and Nanomedicine…\ninterview respondents till the point where no new aspects related to the definitions were described. The theoretical saturation was reached at various points for different research questions depending on the diversity of opinions, stakeholder heterogeneity and scope of debate on the topic."
    }, {
      "heading" : "Informed Consent",
      "text" : "The lead author of this manuscript (PS) conducted all 46 interviews (in person or via telephone or a Skype call) in English from October 2013 till November 2014. Oral informed consent was obtained from each respondent at the beginning of an interview, which also included permission to record the interview. All interviews were recorded on a hand held audio device except one for which the researcher was asked not to record the conversation, but to take hand-written notes. The respondents were informed about how their anonymity and confidentiality would be ensured. We removed all respondent identifiers such as name, affiliation, country and the details of the products they were developing to minimize identification. Respondents were also told that they could choose to not answer particular questions if they felt uncomfortable and that they could ask for audio recording to be stopped for particular sections of the interviews. The same procedure was used to obtain informed consent and permission for audio recording for the interviews conducted on the telephone or via a Skype call. This approach was essential to build a trusting relationship with the respondents since many were concerned about sharing sensitive and proprietary information of early clinical trials of their investigatory products with a social science researcher. Their concerns were also linked to the fact that the field of nanomedicine is comparatively small, yet specialized, and has a very close-knit scientific community."
    }, {
      "heading" : "Interviews and Transcription",
      "text" : "The interviews lasted between 20 min and 2 h depending on the respondent’s availability and their interest in sharing their experience; the average interview was 50 min. Eighteen interviews were conducted in person while the remaining 26 were carried out either via the telephone or a Skype call since travel to different countries in Europe and North America was not possible due to the time and money involved. We were aware that interviewing in person compared to on the phone or Skype would impact the quality of the data. It is generally easier to develop rapport with a respondent when interviewing in person compared to a phone conversation. We discuss this in more detail in the section on study limitations. PS with assistance from four team members (data assistants who had signed confidentiality agreements) transcribed all the interviews in full. PS checked all 46 interviews for accuracy against the audio recordings. As per our agreement with the respondents, we sent the transcript of each interview to the respondent to verify the accuracy of the content since some interviews (at least in part) were highly technical. Respondents were also encouraged to provide any additional thoughts they had when reviewing their transcript or thoughts that had arisen after the interview. We received feedback from only 13 respondents. A total of 17\nP. Satalkar et al.\nrespondents were re-contacted in person at a conference and told PS that they had briefly reviewed their transcripts but had been unwilling to go through all 20–30 pages and had assumed the transcripts were accurate. The remaining 16 transcripts were assumed to be correct and acceptable to the respondents."
    }, {
      "heading" : "Data Analysis",
      "text" : "The transcripts of all interviews formed the basic data for this research. The transcripts were read repeatedly to have a thorough understanding of the data. PS coded all interviews using qualitative data analysis software (MAXQDA, edition 11.0.2 licensed by the University of Basel) using deductive coding methods. The research questions guided the deductive data coding. The codes were built into subthemes and themes and compared across all respondents. A second author (DS) conducted a manual data analysis using the same deductive coding and the codes and themes were compared between the two approaches (software assisted vs manual). Similarity and differences in coding were discussed amongst the researchers who are also authors of this manuscript until a consensus was reached.\nIn the sections that follow, we first describe the characteristics of our respondents followed by key official definitions of nanotechnology and nanomedicine. Then we present the definitions of nanomedicine provided by our respondents during interviews and compare them with the official definitions. Finally we discuss the influence of this diversity in the definition of nanomedicine on the regulatory and ethical review process of FIH trials in nanomedicine."
    }, {
      "heading" : "Results",
      "text" : ""
    }, {
      "heading" : "Respondent Profiles",
      "text" : "A total of 21 of 46 respondents were based in Switzerland, while the remaining 25 worked in Germany, The Netherlands, the United Kingdom, Spain, Portugal, Denmark, Norway, Austria, Hungary, Israel, Canada and the US. Almost half of our respondents (20/46) described themselves as academics or scientists affiliated with a university or research institution. Respondents had diverse disciplinary backgrounds such as medicine, molecular biology, biochemistry, material science, physics, toxicology, pharmaceutical science and organic chemistry. Eight respondents represented SMEs, which play a crucial role in early translational research and particularly in obtaining a ‘proof of concept’ in man. SMEs are university spin-offs, often headed by academics who start a company and are funded by governmental seed grants and/or investment by venture capitalists. Eight of our respondents represented large pharmaceutical companies either as researchers, clinical research managers, consultants or regulatory affairs experts. Six respondents brought in expertise in ethics either as members of EC or institutional review boards (IRB) or being the members of national and international advisory commissions on translational research. Two respondents were affiliated with drug regulatory authorities. We also included one representative each from a venture capitalist\nDefining Nano, Nanotechnology and Nanomedicine…\ngroup and a patient advocacy organization. Many of our respondents had dual roles or experiences at least during some part of their professional career. A large number of academic scientists also supported SMEs as members of their advisory boards. The diversity of disciplinary backgrounds, geographic locations and professional roles helped us to gather views and experiences across a broad range of topics and issues, which was the goal of our exploratory qualitative research."
    }, {
      "heading" : "Official Definitions of Nanotechnology and Nanomedicine",
      "text" : ""
    }, {
      "heading" : "National and International Scientific Bodies’ Definitions",
      "text" : "To understand the evolution of definitions of nanotechnology and nanomedicine, it is necessary to start with publically funded research programs in this field in the US as well as in Europe. The National Nanotechnology Initiative (NNI) was launched, in 2001, in the US which led to significant funding in the field and the development of ‘centers of excellence’ in nanomedicine across the US. The NNI defines nanotechnology and nanomedicine as follows:\nNanotechnology is the understanding and control of matter at dimensions between approximately 1 and 100 nanometers, where unique phenomena enable novel applications. Encompassing nanoscale science, engineering, and technology, nanotechnology involves imaging, measuring, modelling, and manipulating matter at this length scale. Nanomedicine is the application of nanotechnology to medicine (National Science and Technology Council 2014).\nIn contrast, the European Science Foundation (ESF) defines nanomedicine as ‘‘the science and technology of diagnosing, treating, and preventing disease and traumatic injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body’’ and further highlights five key disciplines of nanomedicine: analytical tools; nanoimaging; nanomaterials and nanodevices; novel therapeutics and drug delivery systems; and clinical, regulatory, and toxicological issues (European Science Foundation 2004).\nFinally, the European Technology Platform on Nanomedicines (ETPN) defines nanomedicine as ‘‘the application of nanotechnology to health. It exploits the improved and often novel physical, chemical, and biological properties of materials at the nanometric scale. Nanomedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases’’ (European Technology Platform on Nanomedicine—Nanotechnology for Health 2005).\nThe examples above demonstrate the diversity in nanotechnology and nanomedicine definitions. The European Science Foundation’s definition focuses on broad aspects and components of nanomedicine, but does not elaborate on nanotechnology per se. However, the National Nanotechnology Initiative emphasizes the defining character of nanotechnology and refers to nanomedicine as the application of nanotechnology in medicine. This definition is the only one among the three mentioned above that defines nanoscale in terms of size dimension, i.e. from 1 to 100 nm. The definition of nanoscale is the starting point of the differences\nP. Satalkar et al.\nin size-based definitions of nano, nanomaterials and nanomedicine as we describe further in our results."
    }, {
      "heading" : "Drug Regulatory Authorities’ Definition",
      "text" : "Drug regulatory authorities are closely involved with the development, research and licensing of diagnostic and therapeutic products that harness nanotechnology. We also examined the definitions provided by key drug regulatory authorities representing the geographic distribution of our respondents. The US Food and Drug Administration’s (FDA) recently finalized ‘guidance for industry regarding FDA regulated products involving applications of nanotechnology’ highlighted two points to consider while regulating a product based on nanotechnology.\n1. Whether a material or end product is engineered to have at least one external\ndimension, or an internal or surface structure, in the nanoscale range (approximately 1 nm to 100 nm); and 2. Whether a material or end product is engineered to exhibit properties or\nphenomena, including physical or chemical properties or biological effects that are attributable to its dimension(s), even if these dimensions fall outside the nanoscale range, up to one micrometer (1,000 nm).\nIt must be noted that these guidelines also state that the recommendations are nonbinding (US Food and Drug Administration 2014).\nThe European Medicines Agency (EMA) (2006) defines nanomedicine as ‘‘the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often novel physical, chemical and biological properties of materials at nanometer scale’’. In the same document, the EMA describes nanometer scale as ranging from atomic levels of 0.2–100 nm.\nIn its application form for investigational medicinal products (IMPs), Swissmedic, the authority regulating medical products in Switzerland, requires investigators to elaborate and specify whether the IMP contains nanoparticles with at least one dimension in the nanoscale (1–1000 nm) and whether the IMP has a function and/or mode of action based on nanotechnology characteristics either in the active substance or adjuvant. Swissmedic’s focus is clearly on size as well as function or mode of action, thus making it more specific than other definitions."
    }, {
      "heading" : "Stakeholder Definitions",
      "text" : "Our respondents were encouraged to define nanomedicine in terms of properties that they believed were essential. They were all aware of the various definitions provided by multiple scientific bodies and authorities and many of the respondents were closely involved in the debates surrounding nano-nomenclature in general and defining nanomedicine, in particular. Below we present definitions provided by our stakeholders under various themes.\nDefining Nano, Nanotechnology and Nanomedicine…"
    }, {
      "heading" : "Based on Size",
      "text" : "Material with at least one dimension in the nano scale has been the key property of nanotechnology and this is reflected in the definitions of nanomedicine. But there is an ongoing debate about defining the scale that should be limited as the nanoscale. Below are some of the responses from our respondents highlighting this tension.\nEverything that is in the range of one to 100 nm is nanotechnology and when you apply it in medicine it is called nanomedicine. A lot of people don’t differentiate anymore between molecular medicine and nanomedicine. We have [had] molecular medicine for a long time. R6\nThere are many definitions. One says up to 100 nm, they don’t give you a lower limit. Other says up to 1000 nm. The definition, which is applied in politics in Germany, no I am sorry in the EU, is between one and 100 nm. R14\nHowever, there were also voices that were critical of a size-based definition as described below.\nThere is no really good definition to be honest and there are several ones. I tend to define nanomedicine as something larger than antibodies, but that is my personal one. Indeed, anything defined only by size is flawed. If you define it [nanomedicine] as up to 1000 nm, what happens to a product that is 1001 nm? Drugs don’t fit nicely in a size dimension. This is not a step function, rather a linear function. Any attempts to spend more time on definition of nanomedicine to be honest are futile. R10"
    }, {
      "heading" : "Based on the Properties of the Material",
      "text" : "Most definitions provided by our respondents centered on the fundamental properties of the material under investigation. They attributed various properties that should be considered while defining nanomedicines as can be seen below.\nPhysical Chemical Properties\nNanomedicine is the use of nanoparticles to elicit a therapeutic response that would not be efficacious in the absence of nanoparticles. Nanomedicine is something that is beneficial because of inherent nature of nanoparticle and not just because they are very small. It is the inherent nature of nanoparticle that enhances or enables a high therapeutic efficacy, which we will not have otherwise. R11\nHowever, a few respondents also questioned the importance given to the properties of nanomaterials and their uniqueness, arguing that there are no longer any unpredictable properties owing to the advances in tools and characterization techniques. They argued that it is fully possible to predict the behavior of nanoparticles in biological systems.\nP. Satalkar et al.\nIt [nanomaterials definition] is just the size definition merely and there are no unpredictable properties. They are all predictable. They were not predictable may be 10 years ago but they are now. R10\nOrganic/Inorganic Our respondents repeatedly discussed the chemical composition of nanoparticles used in medical applications mainly in terms of an organic or inorganic nature. This formed the foundation for discussion on nano-toxicity and the risks associated with the accumulation of nanoparticles in human body.\nI think, first we have to separate between organic and inorganic nanoparticles. Why? Organic nanoparticles are all these liposomes and micelles. They are well known, well used. And there is the nano in size only. They are generally below 100 nm if you go by EU definition. But if you go to inorganic nanoparticles, we change their physical, chemical, magnetic, electric and optical properties. And from a scientific point of view, if you get a size where you change these properties, only then you can speak about nanoparticles. For example, in iron oxide particles, this happens below 20 nm, above this size, they have same property as bulk iron oxide. And this size at which material shows changed properties is different for different materials. R15"
    }, {
      "heading" : "Ability to be Metabolized",
      "text" : "When we talk about nanoparticles, we need to remember there are different classes of nanoparticles. Iron oxide nanoparticles have a solid core meaning they are really solid, but when you speak about albumin, it is a bit different. It is a polymer; it is a biopolymer that you already have in your body. The truth is, we need to define [the] classes where we put our nanoparticles and also consider whether they can be metabolized by the body or not. If it takes a long time to metabolize, you need to know how long it will take, where in body will these particles be stored? R19\nA large number of respondents made a clear distinction between organic and inorganic nanomaterials and more concerns were raised about inorganic nanoparticles that the human body is not exposed to in its physiological function due to their interaction with biological systems and metabolism. Respondents were troubled by the prospect of using carbon nanotubes as a drug-delivery method due to their similarity to the micro-needle structure of asbestos and their potential to cause cancer.\nI saw so many talks on carbon nanotubes being used for drug delivery. And the starting point of that, they are toxic. So you are wasting your time unless you are just doing basic research to see what kind of toxicity you are going to see. And then to use those to transport drugs across blood brain barrier it’s even more ridiculous. And then the EU putting in a billion dollars for carbon nanotube research for medicine is beyond ridiculous! So I don’t know what is going on, anymore. It’s crazy! R31\nDefining Nano, Nanotechnology and Nanomedicine…\nAnother respondent could see very limited potential for carbon nanotubes as a method for drug delivery, but anticipated significant regulatory hurdles as described below.\nI would never use carbon nanotubes as [a] drug-delivery method because it is not biodegradable, the body does not know that structure. What will happen? These materials themselves… it would not be approved by the EMA or by the FDA. Very simple! Maybe if you could demonstrate that with a nanotube a specific cancer can be cured, you have a big step in favor, superior for instance to liposomes. Maybe in cancer, because in cancer there is a lot allowed. It is maybe better to survive for some years and have a toxic substance in your body than die too early. So you could see an application for such systems, but still I would think you would have a lot of trouble at the regulatory level R24.\nSome respondents countered that not all inorganic nanoparticles are dangerous as the human body is used to handling and metabolizing these particles. This was particularly discussed in regard to iron complexes, which have been used to treat anemia successfully.\nPharmacodynamic Properties Pharmaceutical scientists emphasized the interaction of nanosize particles with pharmacokinetics and pharmacodynamics. Their definition of nanomedicines centered on the pharmaceutical goal to achieve a higher concentration of active drug at a desired site by improving absorption or prolonging half-life. This approach could lead to a reduction in a required dose, and thus associated side effects as well as a reduction in the cost of treating a disease.\nI consider nanoparticles as a vehicle for drug delivery. When you incorporate your drug in a nanostructure, it changes its solubility, physical and chemical stability, and its interaction with the biological systems due to presence of nanostructure or a nanocarrier. For me that is changing [the] properties of a drug. Usually, per definition nano means below 100 nm because below this size you have different properties of material. But, from the pharmaceutical perspective, reducing the size of a drug from micrometers to 400 or 500 nm makes a significant change in the performance of a drug. Why? Because this drug due to its reduced size will dissolve faster, more drug will get absorbed in the intestine. So just by reducing the size of particles and increasing the surface area, you will have higher absorption of the drug. If that happens at 400 nm, who cares? If you are increasing the bioavailability of a drug by reducing the size to 400 nm, it is still nano. It is important for the scientist to think- what does nano contribute to performance of your drug? R41\nAbility to be Engineered and Complex Multimodular Assembly Some of our respondents specifically focused on the engineered aspects of a product or the manipulation of the material as essential to be qualified as a nanoproduct.\nWhile defining nanomedicine, one thing is size, you are speaking about 1-1000 nm. I would say if you have a macromolecule, or a molecular\nP. Satalkar et al.\nassembly where you can put different targets, different carrier molecules and you can incorporate different active compounds inside this structure, you can make an active compound reach the target better, or you can improve the solubility of a compound which was previously insoluble. For me, nanomedicine has this complex multi-modular assembly. R25\nNanomedicine needs to be defined on case-by-case basis. If you take monoclonal antibodies, they are certainly in that size range, but I won’t call then nanomedicine. For me, nanotechnology also has engineered component to it. R39\nSub-classes of Nanoparticles Some respondents stated that they were not concerned about the definition of nanomedicine, but instead claimed that it is important to refine the sub-classification of these nanoparticles. They argued that as the field of nanomedicine and nanocharacterization evolves, it has to reflect on the classification of various nanoparticles rather than making blanket statements about the biodegradability and composition of nano materials. These respondents argued for the need to assess each new product with nanotechnology on a case-by-case basis till we have sufficient knowledge and experience with different classes of particles and over a long period of time.\nDefinition per se, I don’t have any problem, but I think it is time to start generating sub-categories, the binning process [classifying, putting it in different bins or categories] I mentioned to you before. Definition of a molecule is equally broad, but we talk about small molecules, polymers, micro molecules, peptides, so on and so forth. R13"
    }, {
      "heading" : "Based on Size and Properties",
      "text" : "A few respondents highlighted the importance of considering both size and properties when assessing nanoparticles, since these two functions are often interdependent.\nThere might be an aspect of size in definition of nanomedicine somewhere during manufacturing process or in the end product. So size is important, but it is not exclusive. I think what is much more important is to characterize such drugs or particles and their behavior in biological systems because these products behave very differently than classic molecularly dispersed products in terms of pharmacokinetics, half-life and eventual elimination from the body. R32\nOther respondents stressed the need of mimicking naturally occurring molecules in the body, which are at the nanoscale, with the goal of enhancing drug delivery methods.\nThe way that you really learn about how to deliver a drug in the body is not by collaborating with anybody who is using gold nanoparticles or polymers or dendrimers or any of this other stuff, it is to see what nature does. So the way\nDefining Nano, Nanotechnology and Nanomedicine…\nnature delivers some of its hydrophobic materials like cholesterol, which actually forms a crystal, is to turn it into more amorphous material called cholesterol ester or cholesterol oleate and form nanoparticles which are called low density lipoprotein (LDL) molecules. They are 25 nm and if you want to deliver something to cancers, cancers don’t eat gold. They don’t eat plastics, calcium, and phosphate. What they eat is LDL particles. R7"
    }, {
      "heading" : "Based on Discipline",
      "text" : "Nanotechnology and nanomedicine are highly interdisciplinary fields and this is clearly reflected in the definitions of nanomedicine.\nInterdisciplinarity of the Field\nYes, the definitions of nanomedicine are diverse and that is probably due to the fact that the field in itself is highly interdisciplinary. We have chemistry, physics, and material sciences and then we have applications in biology, microbiology, biochemistry, medicine and pharmaceutical sciences. So, everybody of course has his or her own disciplinary background even though they work in nanomedicine and they work with different definitions as far as understanding of the field is concerned. That is only natural. R35\nIn the context of this interdisciplinarity, a few respondents argued for defining the parent technology rather than the medical application.\nI am not sure if nanomedicine exists as a separate thing. I believe there is nanotechnology that is used in nanomedicine. But nanomedicine should not be a discrete branch of therapeutic endeavor. So, the important thing is to try and define the technology rather than trying to partition a separate area in medicine because then technology can offer a huge range of different applications in different clinical circumstances. R36\nA few respondents were critical of the focus on changed physical and/or chemical properties of matter at the nanoscale even though they understood its origin in the respective disciplines. They argued that biological properties are essential and more important than particle size to fully assess the breadth and scope of the field of nanomedicine.\nFor me biology has to be considered as well, especially the behavior and change of properties of these materials in interaction with biological systems. And I am fighting for increasing the upper limit from 100 to a few hundred nm; perhaps we could go up to 500 nm because in biological systems, even particles larger than 100 nm demonstrate the behavior of nano. Only if you double that, you go to one micron or 1000 nm, they change. They don’t penetrate the cell membrane like many nanoparticles do. So as far as the interaction of nano with biological system is concerned, the limit is higher, it is higher than 100 nm. R14\nMany of our respondents were vocal about the semantics of nanomedicine and how the terminology has evolved over last few decades.\nP. Satalkar et al.\nLiposomes have been around since 1960s, but in last 20 years, they have been rebranded as nanomedicines or liposomal nanoparticles. I would say that for me it should be below 150 nm. What I do with real (emphasis added) nanotechnology is develop the materials whose properties are different because of nanoscale, for example, quantum dots. That is really nanotechnology in the sense that something happens to these materials because of their size. But, these things are much smaller; they are below 10 nm. But, if you are in pharmacology, you can say that these nanoparticles follow the pharmacokinetics of a therapeutic compound and that is what I want to achieve. But, if you look at them from the perspective of physical chemistry, which I am also involved in, it becomes only interesting and truly nano at a scale about 10 nm where the materials actually change their properties. So, it all depends on your perspective. R28\nThe view expressed above also shows the tension between the disciplines. The ‘real’ nanotechnology as perceived by professionals working in the field of physical chemistry as compared to the ‘applied’ nature in pharmaceutical sciences, which tends to be more open and inclusive of larger molecules up to a micron level, as long as these larger molecules can help achieve a desired therapeutic or pharmacodynamic effect.\nNano is an Academic Phenomenon Respondents affiliated with large pharmaceutical companies often discussed the ‘buzz’ of nanomedicine as an academic phenomenon and pointed out that the label ‘nano’ has less importance in terms of drug development.\nAnother problem is that this definition of nanomedicine is not really accepted by pharmaceutical industry. [The] ‘‘nano label’’ is dropped in industry when they begin drug development. Drugs are not developed as nano drugs; they are developed as drugs. R11\nThere is a typical pharmaceutical approach to this definition. They consider all that is below micron that is below 1000 nm as nano. So in that sense, their definition is not even compatible with the EU definition. R15\nThe definition of nano as one to 100 nm comes from National Nanotechnology Initiative. But it has no relevance to drugs or pharmaceutical products because drug companies don’t care about size. They are more interested in creating safe, effective and superior drug formulations. So I think it is more accurate to use definition as one to 1000 nm or below micron as far as drug development is concerned. R31"
    }, {
      "heading" : "Based on Audience",
      "text" : "One of our respondents described how the audience he is talking to determines which definition he would use.\nDefining Nano, Nanotechnology and Nanomedicine…\nFrom scientific (material science) point of view, we refer to nano if we have real change in properties and I use this definition when addressing scientific audience because they understand exactly what I am talking about. But, when I talk to the general public or medical doctors, I use the EU definition which states that half of the particles must be below 100 nm because our more scientific definition is too complicated for them since we have a different value for each material at which the properties change. For iron oxide it is 20 nm whereas for titanium di oxide it is about 10 nm. To go further, while talking to pharmaceutical science people, I have to talk about definition, which is below a micron even though that definition is not compatible with EU definition. And then again, there is this political discussion about REACH [Registration, Evaluation, Authorization and Restriction of Chemicals] regulation. If you claim that the material you are working with is nano and has new properties, you are in danger that you have to show that this new material is safe and have to go through whole accreditation process under REACH. R15"
    }, {
      "heading" : "Based on Pathology and Route of Administration",
      "text" : "An alternative definition of nanomedicines takes into account the pathology under consideration.\nThe size definition is really arbitrary; nano aspect relates to the opportunities that the nature offers. If you think about an enhanced permeability and retention (EPR) effect, it won’t work with your molecule, which is below 1000 nm. You will need molecules that are in rage of 100 to 150 nm or 50 nm or even smaller. So I had rather use a more dynamic definition of nano related to what nature is enabling nano to do. If you have to treat a bacterial infection which is primarily located in macrophages in liver, then may be a formulation at 500 nm is more appropriate in this situation because these particles containing drugs will get sequestered in the liver and you can also include higher amount of drug in these particles thus providing more effective treatment. R24\nAnother participant demonstrated how the route of drug administration would influence the definition.\nThe particle size of below 100 nm is crucial to achieve desired biological or therapeutic properties only when we inject the formulation systemically. But if you have an application where you can actually acquire particles locally, size is not as important as it is in case of intravenous application. In such a case, having larger particles is an advantage for they can accommodate more active drug ingredients. So for this specific application, I would say nanomedicine is to produce particles below 500 nm. R16\nP. Satalkar et al."
    }, {
      "heading" : "Discussion",
      "text" : "Nanomedicine is an interdisciplinary field and clinical translation involves multiple stakeholders. A crucial finding of our study is the extent to which stakeholders have described the tension between disciplines, target audiences and regulatory bodies when discussing the definition of nanotechnology and nanomedicine. This also highlights how difficult and challenging communication can be among stakeholders, especially if each has their own definition or understanding of nanotechnology or nanomedicine. We argue that clarity in the definition of nanomedicine and the consistent use of a single definition is critical to facilitate translational research in nanomedicine in ethical and transparent ways and to ensure a fair distribution and utilization of available resources. As the field of nanomedicine acquires more knowledge and experience with different classes of nanoparticles, it is also critical that we start focusing on different classes of nanomedicines while discussing toxicity or drug regulation pathways, rather than assessing the whole range of nanomedicinal products with the same tests and against same standards. In this section, we discuss how various stakeholders have influenced the definition of nanomedicine, as well as the impact of multiple definitions on key stakeholders involved in the clinical translation in nanomedicine."
    }, {
      "heading" : "National and International Scientific Bodies and Funding Agencies",
      "text" : "The establishment of the NNI in the US has clearly fuelled research in nanotechnology and it’s the medical applications. The NNI also created ‘Centers of Excellence’ in nanotechnology across the US and generated significant funding for research in nanotechnology (Roco 2011). Unlike biotechnology, which has mainly been supported by start-ups and private companies, nanotechnology has received significant public funding (Paull et al. 2003) as well as fostered a lager industry-academia collaboration (McComas 2012). Similar trends have been seen in Europe with funding from the European Science Foundation and the European Research Council as well as governmental funding schemes in Japan and South Korea (Roco 2005). As funding in the field has improved drastically, so has the number of grant applications. Scholars have also pointed out inadequacies in the current model of peer review based grant assessment and questioned whether commercialization of research is the best way to optimally utilize public funding in science and technology especially when some commercially non attractive yet needed research might never get supported by the industry (Spier and Bird 2003).\nMany scientists working in various scientific disciplines have realized that the work that they have been doing for decades now could fall under the purview of nanotechnology based on nanoscale or if attributed to novel physical, chemical, or quantum properties of material (Drexler 2004). The work that was not originally labeled as nanotechnology or nanomedicine has begun to be re-framed along these lines with the increased availability of funding. Increased funding in the field,\nDefining Nano, Nanotechnology and Nanomedicine…\ncoupled with increased media attention and broad definitions of nanotechnology and nanomedicine can create significant challenges for funding agencies to draw a cutoff point based on a definition alone when assessing these grant applications.\nAs shown in our results, many experts working in nanotechnology and nanomedicine have argued that a mere focus on size of particles is detrimental to a common definition because the change of properties in relation to size of the particle is a continuum rather than distinct size cut-off. They also claimed that in terms of an intervention sometimes size matters, sometimes changed properties are important and sometimes both size and change in properties are crucial to achieve a desired action. Clarity and consistency on a definition and special attention to sizebased characteristics and changed material properties are crucial for funding agencies to distribute available funds across applications with the potential to improve healthcare and ensure transparency in the evaluation of submitted grant applications."
    }, {
      "heading" : "Patent Authorities",
      "text" : "Increased global funding for nanomedicine also has the underlying aim of improving and facilitating successful commercialization of technology to facilitate good returns on investments through public funding (Roco et al. 2011) This heightened focus on the innovation and commercialization of nanotechnology is also reflected in the increase in the number of broad patent applications related to investigational medical products, some aspects of the technology or the process of producing the product. Inconsistent definitions of nanotechnology and nanomedicine create confusion in the assessment and qualification of patent claims as well as drastically increased pending patent applications (Bawa 2007). Patent protection is particularly important for SMEs as it improves their chances of obtaining funding as well as enhancing the value of their product in the competitive world of drug discovery (Bawa et al. 2005). Patent related issues will become increasingly important as the field anticipates the expiration of nanomedicine patents licensed in the 1990s and the future development of nanosimilars (Bremer-Hoffmann et al. 2015; Tinkle et al. 2014)."
    }, {
      "heading" : "Regulatory Authorities",
      "text" : "Nanomedicines and their definition have significant implications for international drug regulatory authorities as well as industrial regulatory and environmental protection agencies. For drug regulatory authorities, it is crucial to account for the complexity of some of the investigational products based on nanotechnology. The drug-device distinction is not always clear, and with the advent of regenerative medicine, one could expect to see complex biological entities with cell-based components on a nano surface or nano scaffolds and other active molecular or chemical entities (Niemansburg et al. 2013). The characterization of nanoparticles has significantly improved over the last two decades, but the long-term toxicity of some nanomaterials still needs to be carefully assessed and will require stronger post-marketing surveillance. As described in the results section, various definitions\nP. Satalkar et al.\nof nanomedicine influence whether a molecule is approved in specific countries, depending on local drug regulatory authorities. Some authorities might be seen as less rigid and more inclusive in terms of the definition of nanomedicine as compared to the others. This could have an impact on the geographic location where trials will be conducted and new drugs will get licensed. Drug development and clinical research is an international enterprise and uniformity in a definition of nanomedicine across key drug regulatory authorities will facilitate translation of nanotechnology into clinical applications. The regulatory authorities need to carefully assess and monitor the use of nanoparticles in food additives, food packaging, and cosmetics as they fall into distinct categories of regulatory pathways and are often less strict than for the drug approval process.\nPharmaceutical Industry and SMEs\nAs described in our results section, it appears that the label ‘nano’ is not significant for large pharmaceutical companies. However, it is crucial for SMEs that often work towards producing ‘proof of concept’ in man (Eaton et al. 2015). SMEs depend on external funding to conduct early clinical translation studies, particularly for FIH trials. This funding comes from international grants or venture capitalists. Only on a successful ‘proof of concept’ in man can an SME out-license their product to the pharmaceutical industry or take the product further into phase I–II trials. The latter requires a large financial investment that SMEs can rarely manage to attract (Eaton 2012). Clarity and consistency in the definition of nanomedicine can improve the assessment for funding and allow SMEs to contribute to translational research."
    }, {
      "heading" : "Ethics Committees",
      "text" : "Clarity and uniformity in the definition of nanomedicine and the consistent use of nano terminology are critical for the ethical review of submitted clinical trial protocols. The role of EC is to ensure human subject safety while evaluating trial protocols involving patients or healthy volunteers. The EC needs to undertake a detailed risk assessment to balance the risks against the potential benefits before approving a clinical trial (Anderson and Kimmelman 2014). The EC also needs to carefully assess the informed consent forms and ensure that the risks and benefits of trial participation are clearly and accurately described in a language that is easy to understand (King 2012). If investigators do not describe the nanomedicinal product under investigation in all the necessary detail, it is likely to adversely affect the ethical review. Whether nanoparticles should be explicitly mentioned in the trial protocol, investigators brochure and informed consent form is a matter of debate and is beyond the scope of this paper. However, to ensure transparency and integrity in research, it can be argued that full disclosure of the nature of the molecule under investigation is needed for a rigorous ethical review (Dresser 2012) and to obtain a valid informed consent. Clarity and uniformity of the definition of nanomedicine would be important to facilitate transparency in clinical trials as well as in the ethical review of this research.\nDefining Nano, Nanotechnology and Nanomedicine…"
    }, {
      "heading" : "Patient Population",
      "text" : "Most nanomedicine has been developed for cancers where there is an unmet need for treatment. However, other chronic diseases are slowly being targeted by nanotechnology based improved therapeutics. In clinical translation and particularly in FIH trials, new interventions are often tested on patients who have no other treatment option (Hug and Hermerén 2011). Patients approached to participate in clinical research need to be provided with all the necessary information regarding the technology and the characteristics of the proposed treatment to make a truly informed choice. Many patients trust their physicians and hope to receive all the relevant information about the product under investigation from them (Anderson and Kimmelman 2014). But some may actually undertake internet research on their own. For patients to provide a meaningful informed consent, it is critical that they have all necessary information about the product they will be given and clarity on the nanotechnology-based formulation should be part of this information."
    }, {
      "heading" : "General Public",
      "text" : "Public acceptance of a technological intervention is essential for its implementation, improvement and access. The debate on genetically modified organisms in Europe, where the public was not clearly or adequately informed, showed the importance of honest and open communication. Literature on public engagement in nanotechnology has pointed out the need for such engagement (Cormick 2012; Cormick and Hunter 2014; Krabbenborg and Mulder 2015; Cacciatore 2014) and has also raised critical questions such as; what is the public? How does one engage those who are unengaged and what tools could be used to improve public engagement (Cormick 2009). Educating the public with the scientific evidence related to nanotechnology, and being transparent about the possible advantages and potential harms of a new technology is important (Priest 2009). Public opinion shapes the political and regulatory environment and influences the level of funding available for particular technology. Some of our respondents argued that nanotechnology is too complicated for the general public to understand and that attempts to inform the public about the potential risks and benefits is likely to negatively polarize their opinion. However, this line of thinking is dangerous. Even if some patients and citizens do not understand the complexity of nanotechnology, assuming that no one needs to be informed compromises the public’s right to information. With access to information and research databases, the public can obtain more information about a product or technology and might even feel deceived if certain information was underplayed by the scientists and experts. This action would erode public trust in science and prove detrimental to research and development (Master and Resnik 2013; Resnik 2011). It is important to find innovative ways to explain the complexity of nanomaterials and nanoparticles, and their potential use and risks to the public in scientifically accurate yet understandable ways. This could be achieved through various means such as school education and introducing children to basic concepts of nanotechnology, participatory interactions between the scientific experts and general public and by\nP. Satalkar et al.\nensuring a balanced and scientifically accurate coverage of nanotechnology-related debate in media."
    }, {
      "heading" : "Limitations",
      "text" : "To the best of our knowledge, no other empirical studies have looked at diversity in the definition of nanomedicine. Our purposive sampling technique allowed us to access a wide spectrum of viewpoints and strengthened our findings. However, there were 12 stakeholders who did not reply to our emails, phone calls, and letters. Whether the views of those 12 are drastically different from those of the 46 who were interviewed is unclear. The stakeholders we interviewed explained the refusal of the others in terms of extremely busy schedules and a preoccupation with higher priority tasks than contributing to this research project.\nThe aim of our exploratory qualitative research was to document the diversity in definitions of nanotechnology and nanomedicine and to examine how this affects translational research. Our research only focusses on stakeholders in Europe and North America and we are clearly missing the voices from China, Japan, Australia, India and other Asian countries where research in nanotechnology and nanomedicine is ongoing. We do not claim that our findings can be generalized to all stakeholders of translational nanomedicine across the world. Further research with homogeneous populations such as SMEs, large pharma, scientists and academics using quantitative research methods is warranted.\nThe fact that one interviewer conducted all the interviews might raise a concern of systematic bias in the collected data; however we also believe that the consistency and standardization of the interview technique was an advantage. Openended interview questions allowed respondents to elaborate on their viewpoints and these expert stakeholders were unlikely to be influenced by the viewpoint of the interviewer. The difference in opinion of the interviewer and the interviewee in fact led to interesting debates that further teased out the nuances of the topic. Analysis of the interviews by generating codes and building themes was carried out by the research team to further minimize systematic bias that could have arisen if the data had been analyzed by only one researcher."
    }, {
      "heading" : "Conclusion",
      "text" : "Nanomedicine is more than the application of nanotechnology in medicine and health care. It is a key enabling technology drawing on expertise and techniques from many scientific disciplines. It has attracted significant attention from funding agencies, policy makers and the general public, and has also been criticized as a buzzword or hype. For successful translation of basic science research in nanotechnology into clinical applications, transparency at each stage of technological development and trust among various stakeholders and general public are critical. This is where a clear, scientifically comprehensive and consistent definition of nanomedicine and further sub classification of nanoparticles used in medicines\nDefining Nano, Nanotechnology and Nanomedicine…\nhas a role to play. This definition and sub-classification will facilitate progress along the translational pathway without being too restrictive and improve communication across the stakeholders. This is not an easy balance. Convenient usage of one definition over others or dropping of word ‘nano’ when deemed unfavorable will prove dangerous in the long run as it will adversely affect the public’s trust and transparency in scientific research. An open and honest dialogue across the stakeholders, the general public and politicians is essential if we truly want to exploit the potential of this key enabling technology to improve human health and wellbeing.\nAcknowledgments We are thankful to all the respondents of this study who gave us their valuable time for the interviews in spite of their busy work schedules. We are also thankful to the constructive comments provided by two anonymous reviewers which helped us improve the manuscript further.\nAuthor Contributions BE had the original idea, developed the project and wrote the research grant. PS conducted all the interviews, analyzed the data, conceived the idea for the manuscript and wrote the first draft. DS was involved in data analysis. Both BE and DS provided comments and contributed to the strengthening of the arguments. All three authors contributed to writing of the final manuscript and agree with the submission.\nFunding This research project was funded by the ‘Swiss National Science Foundation’ under project Grant No. PDFMP3_137194/1.\nCompliance with Ethical Standards\nConflict of interest None.\nEthical Approval This research project was approved by the ethics commission of Basel Stadt and Basel Land."
    } ],
    "references" : [ {
      "title" : "The coming era of nanomedicine",
      "author" : [ "F. Allhoff" ],
      "venue" : "The American Journal of Bioethics, 9(10), 3–11. Anderson, J. A., & Kimmelman, J. (2014). Are phase 1 trials therapeutic? Risk, ethics, and division of",
      "citeRegEx" : "Allhoff,? 2009",
      "shortCiteRegEx" : "Allhoff",
      "year" : 2009
    }, {
      "title" : "Patents and nanomedicine. Nanomedicine",
      "author" : [ "R. Bawa" ],
      "venue" : "labor. Bioethics,",
      "citeRegEx" : "Bawa,? \\Q2007\\E",
      "shortCiteRegEx" : "Bawa",
      "year" : 2007
    }, {
      "title" : "Nanomedicines in the European translational",
      "author" : [ "S. 137–152. Bremer-Hoffmann", "V. Amenta", "F. Rossi" ],
      "venue" : null,
      "citeRegEx" : "Bremer.Hoffmann et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Bremer.Hoffmann et al\\.",
      "year" : 2015
    }, {
      "title" : "Building an ethical foundation for first-in-human nanotrials",
      "author" : [ "R. Dresser" ],
      "venue" : "The Journal of Law, Medicine & Ethics, 40(4), 802–808.",
      "citeRegEx" : "Dresser,? 2012",
      "shortCiteRegEx" : "Dresser",
      "year" : 2012
    }, {
      "title" : "Nanotechnology: From Feynman to funding",
      "author" : [ "K.E. Drexler" ],
      "venue" : "Bulletin of Science, Technology & Society, 24(1), 21–27.",
      "citeRegEx" : "Drexler,? 2004",
      "shortCiteRegEx" : "Drexler",
      "year" : 2004
    }, {
      "title" : "Nanomedicine (s) under the microscope",
      "author" : [ "R. Duncan", "R. Gaspar" ],
      "venue" : "Molecular Pharmaceutics,",
      "citeRegEx" : "Duncan and Gaspar,? \\Q2011\\E",
      "shortCiteRegEx" : "Duncan and Gaspar",
      "year" : 2011
    }, {
      "title" : "Improving the translation in Europe of nanomedicines (aka drug delivery) from academia to industry",
      "author" : [ "M. Eaton" ],
      "venue" : "Journal of Controlled Release, 164(3), 370–371.",
      "citeRegEx" : "Eaton,? 2012",
      "shortCiteRegEx" : "Eaton",
      "year" : 2012
    }, {
      "title" : "Delivering nanomedicines to patients: A practical guide. Nanomedicine: Nanotechnology",
      "author" : [ "M. Eaton", "L. Levy", "O.M. Fontaine" ],
      "venue" : "Biology and Medicine,",
      "citeRegEx" : "Eaton et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Eaton et al\\.",
      "year" : 2015
    }, {
      "title" : "The big picture on nanomedicine: The state of investigational and approved nanomedicine products",
      "author" : [ "M.L. Etheridge", "S.A. Campbell", "A.G. Erdman", "C.L. Haynes", "S.M. Wolf", "J. McCullough" ],
      "venue" : "Nanomedicine: Nanotechnology, Biology and Medicine,",
      "citeRegEx" : "Etheridge et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Etheridge et al\\.",
      "year" : 2013
    }, {
      "title" : "Nanomedicine—An ESF-European Medical Research Councils (EMRC) forward look report",
      "author" : [ "European Science Foundation." ],
      "venue" : "Strasbourg Cedex, France.",
      "citeRegEx" : "Foundation.,? 2004",
      "shortCiteRegEx" : "Foundation.",
      "year" : 2004
    }, {
      "title" : "Nanomedicine and society",
      "author" : [ "M. Ferrari", "M. Philibert", "W. Sanhai" ],
      "venue" : "Clinical Pharmacology and Therapeutics,",
      "citeRegEx" : "Ferrari et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Ferrari et al\\.",
      "year" : 2009
    }, {
      "title" : "Concepts of risk in nanomedicine research",
      "author" : [ "L.F. Hogle" ],
      "venue" : "The Journal of Law, Medicine & Ethics, 40(4), 809–822.",
      "citeRegEx" : "Hogle,? 2012",
      "shortCiteRegEx" : "Hogle",
      "year" : 2012
    }, {
      "title" : "Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies",
      "author" : [ "K. Hug", "G. Hermerén" ],
      "venue" : "The Journal of clinical ethics,",
      "citeRegEx" : "Hug and Hermerén,? \\Q2011\\E",
      "shortCiteRegEx" : "Hug and Hermerén",
      "year" : 2011
    }, {
      "title" : "Healthy women from suspected hereditary breast and ovarian cancer families: The significant others in their lives",
      "author" : [ "R. Kenen", "A. Arden-Jones", "R. Eeles" ],
      "venue" : "European Journal of Cancer Care,",
      "citeRegEx" : "Kenen et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Kenen et al\\.",
      "year" : 2004
    }, {
      "title" : "Predicting harms and benefits in translational trials: Ethics, evidence, and uncertainty",
      "author" : [ "J. Kimmelman", "A. John London" ],
      "venue" : "PLoS Medicine,",
      "citeRegEx" : "Kimmelman and London,? \\Q2011\\E",
      "shortCiteRegEx" : "Kimmelman and London",
      "year" : 2011
    }, {
      "title" : "Nanomedicine first-in-human research: Challenges for informed consent",
      "author" : [ "N.M. King" ],
      "venue" : "The Journal of Law, Medicine & Ethics, 40(4), 823–830.",
      "citeRegEx" : "King,? 2012",
      "shortCiteRegEx" : "King",
      "year" : 2012
    }, {
      "title" : "Can the pharmaceutical industry reduce attrition rates",
      "author" : [ "I. Kola", "J. Landis" ],
      "venue" : "Nature Reviews Drug Discovery,",
      "citeRegEx" : "Kola and Landis,? \\Q2004\\E",
      "shortCiteRegEx" : "Kola and Landis",
      "year" : 2004
    }, {
      "title" : "Upstream public engagement in nanotechnology constraints and opportunities",
      "author" : [ "L. Krabbenborg", "H.A. Mulder" ],
      "venue" : "Science Communication,",
      "citeRegEx" : "Krabbenborg and Mulder,? \\Q2015\\E",
      "shortCiteRegEx" : "Krabbenborg and Mulder",
      "year" : 2015
    }, {
      "title" : "Theranostic nanomedicine",
      "author" : [ "T. Lammers", "S. Aime", "W.E. Hennink", "G. Storm", "F. Kiessling" ],
      "venue" : "Accounts of Chemical Research,",
      "citeRegEx" : "Lammers et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lammers et al\\.",
      "year" : 2011
    }, {
      "title" : "Nanomedicine–emerging or re-emerging ethical issues? A discussion of four ethical themes",
      "author" : [ "C. Lenk", "N. Biller-Andorno" ],
      "venue" : "Medicine, Health Care and Philosophy,",
      "citeRegEx" : "Lenk and Biller.Andorno,? \\Q2007\\E",
      "shortCiteRegEx" : "Lenk and Biller.Andorno",
      "year" : 2007
    }, {
      "title" : "Hype and public trust in science",
      "author" : [ "Z. Master", "D.B. Resnik" ],
      "venue" : "Science and Engineering Ethics,",
      "citeRegEx" : "Master and Resnik,? \\Q2013\\E",
      "shortCiteRegEx" : "Master and Resnik",
      "year" : 2013
    }, {
      "title" : "Researcher views about funding sources and conflicts of interest in nanotechnology",
      "author" : [ "K.A. McComas" ],
      "venue" : "Science and Engineering Ethics, 18(4), 699–717.",
      "citeRegEx" : "McComas,? 2012",
      "shortCiteRegEx" : "McComas",
      "year" : 2012
    }, {
      "title" : "National nanotechnology initiative strategic plan",
      "author" : [ "National Science", "Technology Council." ],
      "venue" : "http://www.nano.gov/sites/default/files/pub_resource/2014_nni_strategic_plan.pdf. Accessed 13 Sep 2015.",
      "citeRegEx" : "Science and Council.,? 2014",
      "shortCiteRegEx" : "Science and Council.",
      "year" : 2014
    }, {
      "title" : "Regenerative medicine interventions for orthopedic disorders: Ethical issues in the translation into patients",
      "author" : [ "S.L. Niemansburg", "J.J. Van Delden", "W.J. Dhert", "A.L. Bredenoord" ],
      "venue" : "Regenerative Medicine,",
      "citeRegEx" : "Niemansburg et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Niemansburg et al\\.",
      "year" : 2013
    }, {
      "title" : "Investing in nanotechnology",
      "author" : [ "R. Paull", "J. Wolfe", "P. Hébert", "M. Sinkula" ],
      "venue" : "Nature Biotechnology,",
      "citeRegEx" : "Paull et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Paull et al\\.",
      "year" : 2003
    }, {
      "title" : "Opening up nanotechnology dialogue with the publics: Risk communication or ‘upstream engagement’",
      "author" : [ "N. Pidgeon", "T. Rogers-Hayden" ],
      "venue" : "Health, Risk & Society,",
      "citeRegEx" : "Pidgeon and Rogers.Hayden,? \\Q2007\\E",
      "shortCiteRegEx" : "Pidgeon and Rogers.Hayden",
      "year" : 2007
    }, {
      "title" : "Risk communication for nanobiotechnology: To whom, about what, and why",
      "author" : [ "S.H. Priest" ],
      "venue" : "The Journal of Law, Medicine & Ethics,",
      "citeRegEx" : "Priest,? \\Q2009\\E",
      "shortCiteRegEx" : "Priest",
      "year" : 2009
    }, {
      "title" : "Handling worker and third-party exposures to nanotherapeutics during clinical trials",
      "author" : [ "G. Ramachandran", "J. Howard", "A. Maynard", "M. Philbert" ],
      "venue" : "The Journal of Law, Medicine & Ethics,",
      "citeRegEx" : "Ramachandran et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ramachandran et al\\.",
      "year" : 2012
    }, {
      "title" : "Scientific research and the public trust",
      "author" : [ "D.B. Resnik" ],
      "venue" : "Science and Engineering Ethics, 17(3), 399–409.",
      "citeRegEx" : "Resnik,? 2011",
      "shortCiteRegEx" : "Resnik",
      "year" : 2011
    }, {
      "title" : "Ethical issues in clinical trials involving nanomedicine",
      "author" : [ "D.B. Resnik", "S.S. Tinkle" ],
      "venue" : "Contemporary clinical trials,",
      "citeRegEx" : "Resnik and Tinkle,? \\Q2007\\E",
      "shortCiteRegEx" : "Resnik and Tinkle",
      "year" : 2007
    }, {
      "title" : "International perspective on government nanotechnology funding in 2005",
      "author" : [ "M.C. Roco" ],
      "venue" : "Journal of Nanoparticle Research, 7(6), 707–712.",
      "citeRegEx" : "Roco,? 2005",
      "shortCiteRegEx" : "Roco",
      "year" : 2005
    }, {
      "title" : "The long view of nanotechnology development: The National Nanotechnology Initiative at 10 years",
      "author" : [ "M.C. Roco" ],
      "venue" : "M. C. Roco, C. A. Mirkin, & M. C. Hersam (Eds.), Nanotechnology research directions for societal needs in 2020 (pp. 1–28). Netherlands: Springer.",
      "citeRegEx" : "Roco,? 2011",
      "shortCiteRegEx" : "Roco",
      "year" : 2011
    }, {
      "title" : "Innovative and responsible governance of nanotechnology for societal development",
      "author" : [ "M.C. Roco", "B. Harthorn", "D. Guston", "P. Shapira" ],
      "venue" : null,
      "citeRegEx" : "Roco et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Roco et al\\.",
      "year" : 2011
    }, {
      "title" : "Religious beliefs and public attitudes toward nanotechnology in Europe and the United States",
      "author" : [ "D.A. Scheufele", "E.A. Corley", "Shih", "T.-J", "K.E. Dalrymple", "S.S. Ho" ],
      "venue" : "Nature Nanotechnology,",
      "citeRegEx" : "Scheufele et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Scheufele et al\\.",
      "year" : 2009
    }, {
      "title" : "On the management of funding of research in science and engineering",
      "author" : [ "R.E. Spier", "S.J. Bird" ],
      "venue" : "Science and Engineering Ethics,",
      "citeRegEx" : "Spier and Bird,? \\Q2003\\E",
      "shortCiteRegEx" : "Spier and Bird",
      "year" : 2003
    }, {
      "title" : "Nanomedicines: Addressing the scientific and regulatory gap",
      "author" : [ "S. Tinkle", "S.E. McNeil", "S. Mühlebach", "R. Bawa", "G. Borchard", "Barenholz", "Y. C" ],
      "venue" : "Annals of the New York Academy of Sciences,",
      "citeRegEx" : "Tinkle et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Tinkle et al\\.",
      "year" : 2014
    }, {
      "title" : "Guidance for industry considering whether an FDA-regulated product involves the application of nanotechnology",
      "author" : [ "US Food", "Drug Administration." ],
      "venue" : "Biotechnology Law Report, 30(5), 613–616.",
      "citeRegEx" : "Food and Administration.,? 2014",
      "shortCiteRegEx" : "Food and Administration.",
      "year" : 2014
    }, {
      "title" : "The emerging nanomedicine landscape",
      "author" : [ "V. Wagner", "A. Dullaart", "Bock", "A.-K", "A. Zweck" ],
      "venue" : "Nature Biotechnology,",
      "citeRegEx" : "Wagner et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Wagner et al\\.",
      "year" : 2006
    } ],
    "referenceMentions" : [ {
      "referenceID" : 10,
      "context" : "The use of nanotechnology in medicine has the potential to significantly improve human health and wellbeing due to highly accurate and sensitive diagnostic tests (Ferrari et al. 2009), targeted therapeutic interventions (Duncan and Gaspar 2011)and theranostic applications that have a combined approach to diagnose and treat a disease using the same intervention (Lammers et al.",
      "startOffset" : 162,
      "endOffset" : 183
    }, {
      "referenceID" : 5,
      "context" : "2009), targeted therapeutic interventions (Duncan and Gaspar 2011)and theranostic applications that have a combined approach to diagnose and treat a disease using the same intervention (Lammers et al.",
      "startOffset" : 42,
      "endOffset" : 66
    }, {
      "referenceID" : 18,
      "context" : "2009), targeted therapeutic interventions (Duncan and Gaspar 2011)and theranostic applications that have a combined approach to diagnose and treat a disease using the same intervention (Lammers et al. 2011).",
      "startOffset" : 185,
      "endOffset" : 206
    }, {
      "referenceID" : 37,
      "context" : "The interdisciplinary field of nanotechnology and nanomedicine has gained considerable attention from academia, the pharmaceutical industry, various national and international funding and regulatory agencies and the general public (Kostarelos 2006; Wagner et al. 2006; Bawa et al. 2005; Pidgeon and RogersHayden 2007; Scheufele et al. 2009), and has made significant progress along the translational pathway in the last 15 years (Etheridge et al.",
      "startOffset" : 231,
      "endOffset" : 340
    }, {
      "referenceID" : 33,
      "context" : "The interdisciplinary field of nanotechnology and nanomedicine has gained considerable attention from academia, the pharmaceutical industry, various national and international funding and regulatory agencies and the general public (Kostarelos 2006; Wagner et al. 2006; Bawa et al. 2005; Pidgeon and RogersHayden 2007; Scheufele et al. 2009), and has made significant progress along the translational pathway in the last 15 years (Etheridge et al.",
      "startOffset" : 231,
      "endOffset" : 340
    }, {
      "referenceID" : 8,
      "context" : "2009), and has made significant progress along the translational pathway in the last 15 years (Etheridge et al. 2013).",
      "startOffset" : 94,
      "endOffset" : 117
    }, {
      "referenceID" : 11,
      "context" : "Nanotechnology has also raised a number of questions related to risk assessment, risk minimization (Hogle 2012), human and environmental toxicity (Ramachandran et al.",
      "startOffset" : 99,
      "endOffset" : 111
    }, {
      "referenceID" : 27,
      "context" : "Nanotechnology has also raised a number of questions related to risk assessment, risk minimization (Hogle 2012), human and environmental toxicity (Ramachandran et al. 2012), and cost and fair access to the improved interventions across societies (Allhoff 2009).",
      "startOffset" : 146,
      "endOffset" : 172
    }, {
      "referenceID" : 0,
      "context" : "2012), and cost and fair access to the improved interventions across societies (Allhoff 2009).",
      "startOffset" : 79,
      "endOffset" : 93
    }, {
      "referenceID" : 16,
      "context" : "There has also been tremendous pressure to accelerate the translation of basic nano-technological research into bedside clinical applications in medicine (Kola and Landis 2004).",
      "startOffset" : 154,
      "endOffset" : 176
    }, {
      "referenceID" : 19,
      "context" : "However, a high level of uncertainty about potential risks and benefits of nanoparticles and nanomedicines creates significant hurdles along this translational pathway (Lenk and Biller-Andorno 2007; Resnik and Tinkle 2007).",
      "startOffset" : 168,
      "endOffset" : 222
    }, {
      "referenceID" : 29,
      "context" : "However, a high level of uncertainty about potential risks and benefits of nanoparticles and nanomedicines creates significant hurdles along this translational pathway (Lenk and Biller-Andorno 2007; Resnik and Tinkle 2007).",
      "startOffset" : 168,
      "endOffset" : 222
    }, {
      "referenceID" : 14,
      "context" : "Particularly interesting in this regard are ‘first in human’ (FIH) trials of medical applications of nanotechnology, as they pose the highest level of uncertainty in all clinical research (Kimmelman and London 2011).",
      "startOffset" : 188,
      "endOffset" : 215
    }, {
      "referenceID" : 13,
      "context" : "We included stakeholders with views in line with the dominant discourse and those who challenge the dominant views (Devers and Frenkel 2000; Kenen et al. 2004).",
      "startOffset" : 115,
      "endOffset" : 159
    }, {
      "referenceID" : 31,
      "context" : "The NNI also created ‘Centers of Excellence’ in nanotechnology across the US and generated significant funding for research in nanotechnology (Roco 2011).",
      "startOffset" : 142,
      "endOffset" : 153
    }, {
      "referenceID" : 24,
      "context" : "Unlike biotechnology, which has mainly been supported by start-ups and private companies, nanotechnology has received significant public funding (Paull et al. 2003) as well as fostered a lager industry-academia collaboration (McComas 2012).",
      "startOffset" : 145,
      "endOffset" : 164
    }, {
      "referenceID" : 21,
      "context" : "2003) as well as fostered a lager industry-academia collaboration (McComas 2012).",
      "startOffset" : 66,
      "endOffset" : 80
    }, {
      "referenceID" : 30,
      "context" : "Similar trends have been seen in Europe with funding from the European Science Foundation and the European Research Council as well as governmental funding schemes in Japan and South Korea (Roco 2005).",
      "startOffset" : 189,
      "endOffset" : 200
    }, {
      "referenceID" : 34,
      "context" : "Scholars have also pointed out inadequacies in the current model of peer review based grant assessment and questioned whether commercialization of research is the best way to optimally utilize public funding in science and technology especially when some commercially non attractive yet needed research might never get supported by the industry (Spier and Bird 2003).",
      "startOffset" : 345,
      "endOffset" : 366
    }, {
      "referenceID" : 32,
      "context" : "Increased global funding for nanomedicine also has the underlying aim of improving and facilitating successful commercialization of technology to facilitate good returns on investments through public funding (Roco et al. 2011) This heightened focus on the innovation and commercialization of nanotechnology is also reflected in the increase in the number of broad patent applications related to investigational medical products, some aspects of the technology or the process of producing the product.",
      "startOffset" : 208,
      "endOffset" : 226
    }, {
      "referenceID" : 1,
      "context" : "Inconsistent definitions of nanotechnology and nanomedicine create confusion in the assessment and qualification of patent claims as well as drastically increased pending patent applications (Bawa 2007).",
      "startOffset" : 191,
      "endOffset" : 202
    }, {
      "referenceID" : 2,
      "context" : "Patent related issues will become increasingly important as the field anticipates the expiration of nanomedicine patents licensed in the 1990s and the future development of nanosimilars (Bremer-Hoffmann et al. 2015; Tinkle et al. 2014).",
      "startOffset" : 186,
      "endOffset" : 235
    }, {
      "referenceID" : 35,
      "context" : "Patent related issues will become increasingly important as the field anticipates the expiration of nanomedicine patents licensed in the 1990s and the future development of nanosimilars (Bremer-Hoffmann et al. 2015; Tinkle et al. 2014).",
      "startOffset" : 186,
      "endOffset" : 235
    }, {
      "referenceID" : 23,
      "context" : "The drug-device distinction is not always clear, and with the advent of regenerative medicine, one could expect to see complex biological entities with cell-based components on a nano surface or nano scaffolds and other active molecular or chemical entities (Niemansburg et al. 2013).",
      "startOffset" : 258,
      "endOffset" : 283
    }, {
      "referenceID" : 7,
      "context" : "However, it is crucial for SMEs that often work towards producing ‘proof of concept’ in man (Eaton et al. 2015).",
      "startOffset" : 92,
      "endOffset" : 111
    }, {
      "referenceID" : 6,
      "context" : "The latter requires a large financial investment that SMEs can rarely manage to attract (Eaton 2012).",
      "startOffset" : 88,
      "endOffset" : 100
    }, {
      "referenceID" : 15,
      "context" : "The EC also needs to carefully assess the informed consent forms and ensure that the risks and benefits of trial participation are clearly and accurately described in a language that is easy to understand (King 2012).",
      "startOffset" : 205,
      "endOffset" : 216
    }, {
      "referenceID" : 3,
      "context" : "However, to ensure transparency and integrity in research, it can be argued that full disclosure of the nature of the molecule under investigation is needed for a rigorous ethical review (Dresser 2012) and to obtain a valid informed consent.",
      "startOffset" : 187,
      "endOffset" : 201
    }, {
      "referenceID" : 12,
      "context" : "In clinical translation and particularly in FIH trials, new interventions are often tested on patients who have no other treatment option (Hug and Hermerén 2011).",
      "startOffset" : 138,
      "endOffset" : 161
    }, {
      "referenceID" : 17,
      "context" : "Literature on public engagement in nanotechnology has pointed out the need for such engagement (Cormick 2012; Cormick and Hunter 2014; Krabbenborg and Mulder 2015; Cacciatore 2014) and has also raised critical questions such as; what is the public? How does one engage those who are unengaged and what tools could be used to improve public engagement (Cormick 2009).",
      "startOffset" : 95,
      "endOffset" : 180
    }, {
      "referenceID" : 26,
      "context" : "Educating the public with the scientific evidence related to nanotechnology, and being transparent about the possible advantages and potential harms of a new technology is important (Priest 2009).",
      "startOffset" : 182,
      "endOffset" : 195
    }, {
      "referenceID" : 20,
      "context" : "This action would erode public trust in science and prove detrimental to research and development (Master and Resnik 2013; Resnik 2011).",
      "startOffset" : 98,
      "endOffset" : 135
    }, {
      "referenceID" : 28,
      "context" : "This action would erode public trust in science and prove detrimental to research and development (Master and Resnik 2013; Resnik 2011).",
      "startOffset" : 98,
      "endOffset" : 135
    } ],
    "year" : 2015,
    "abstractText" : "Nanotechnology, which involves manipulation of matter on a ‘nano’ scale, is considered to be a key enabling technology. Medical applications of nanotechnology (commonly known as nanomedicine) are expected to significantly improve disease diagnostic and therapeutic modalities and subsequently reduce health care costs. However, there is no consensus on the definition of nanotechnology or nanomedicine, and this stems from the underlying debate on defining ‘nano’. This paper aims to present the diversity in the definition of nanomedicine and its impact on the translation of basic science research in nanotechnology into clinical applications. We present the insights obtained from exploratory qualitative interviews with 46 stakeholders involved in translational nanomedicine from Europe and North America. The definition of nanomedicine has implications for many aspects of translational research including: fund allocation, patents, drug regulatory review processes and approvals, ethical review processes, clinical trials and public acceptance. Given the interdisciplinary nature of the field and common interest in developing effective clinical applications, it is important to have honest and transparent communication about nanomedicine, its benefits and potential harm. A clear and consistent definition of nanomedicine would significantly facilitate trust among various stakeholders including the general public while minimizing the risk of miscommunication and undue fear of nanotechnology and nanomedicine.",
    "creator" : "Springer"
  }
}